US-based HistoSonics has secured the first major insurance coverage for its histotripsy system, amid media speculation of a $2.5bn sale. Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network have created a new medical policy that covers non-thermal histotripsy using the HistoSonics’ Edison system for the treatment of primary and metastatic liver tumours. The policy coverage took effect on 1 February 2025, giving 4.5 million residents in Michigan early access to the treatment if eligible. A broader policy will go into effect on 1 July 2025. The coverage is a win for the treatment modality as HistoSonics looks to grapple for market share amongst more established surgical techniques. Founded in 2009 with technology developed by the University of Michigan, HistoSonics received US Food and Drug Administration (FDA) approval in October 2023 for its Edison system, which uses short pulses of focused ultrasound energy to mechanically destroy and liquefy affected tumours. The therapy, which is delivered via a robotic arm, does not carry the same invasiveness or toxicity as traditional approaches. Edison is the only FDA-approved histotripsy system currently on the market. A 12-month follow-up analysis from the HOPE4LIVER study demonstrated a 90% local tumour control rate observed across all treated tumours, regardless of type or origin. This, HistoSonics says, compares favourably to the current standard of care of local regional therapies at the one year follow-up mark. Current surgical approaches used to kill liver tumours include radiofrequency ablation, microwave ablation, and cryoablation. The company is conducting further clinical trials to expand the system’s use into kidney and pancreatic cancer treatment. The Edison system has been adopted at over 50 medical centres in the US to treat over 1,500 patients. “Liver tumours are often a leading cause of death for patients with serious cancers, and it’s critical that they have access to safe, effective and non-invasive treatment options,” said HistoSonics’ CEO Mike Blue. “This milestone marks an important precedent, and we expect additional states and payers to follow in expanding access to histotripsy for patients with liver tumours across the US.” The coverage is set against a backdrop of acquisition talk, with the Financial Times reporting that major medtech companies are eyeing the histotripsy specialist. Medtronic, GE HealthCare, and Johnson & Johnson (J&J) are all reported to be evaluating the business. Through its investment arm, J&J has been a long-time backer of HistoSonics, the latest cash injection occurring via the participation in a $102m Series D round in August 2024. Story Continues "HistoSonics secures first insurance coverage for histotripsy system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
HistoSonics secures first insurance coverage for histotripsy system
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...